Las Vegas, NV -- (SBWIRE) -- 10/02/2013 -- PennyStockEarnings team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks. Our Today’s Focus is on: Angie's List Inc (NASDAQ:ANGI), MAKO Surgical Corp. (NASDAQ:MAKO), Geron Corporation (NASDAQ:GERN), MannKind Corporation (NASDAQ:MNKD)
Angie's List Inc (NASDAQ:ANGI) managed to keep its fall at -9.74% on above-normal volume of 3.40M shares. The stock settled at $20.30 after floating in a range of $20.25 to $22.62. Its latest price has reached market capitalization of $1.19 billion. Its 52-week range has been $8.95 to $28.32. Angie’s List, Inc. (Angie’s List) operates a consumer-driven service for members to research, hire, rate and review local professionals for critical needs, such as home, health care and automotive services. As of December 31, 2012, the Company offered its service to approximately 1.7 million paying members in 219 local markets in the United States.
Has ANGI Found The Bottom and Ready To Move Up? Find Out Here
MAKO Surgical Corp. (NASDAQ:MAKO) traded up on a volume of 3.39 million, higher than its standard daily volume. Shares have gained 0.14% to $29.55. Over the last twelve months, the stock has gained 69.73% and faced a worst price of $10. MAKO Surgical Corp. (MAKO) is a medical device company, which markets its advanced robotic arm solution, joint specific applications for the knee and hip and orthopedic implants for orthopedic procedures.
For How Long MAKO’s Gloss will Attract Investors? Find out via this report
Geron Corporation (NASDAQ:GERN) settled -0.90% lower at $3.32 on above-normal volume of 3.38M shares during the last trading day. The stock has its 12-month high at $3.95 and 52-week low price was $0.91. It traded in a range of $3.13 to $3.66 during the last trading day. Geron Corporation (Geron) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Will GERN Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, MannKind Corporation (NASDAQ:MNKD) was down on low volume, trading at a volume of 3.33M shares versus its average daily volume of 6.11 million shares. At $5.67, the stock has attained market capitalization of $1.71 billion. MannKind Corporation (MannKind) is a development-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer.
Why Should Investors Buy MNKD After the Recent Fall? Just Go Here and Find Out
PennyStockEarnings.com is keen to discover penny stocks with the potential to make short and long-term gains.
PSE Team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks.
PLEASE NOTE WELL: The employees of PennyStockEarnings.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockEarnings.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockEarnings.com is not offering securities for sale. Neither PennyStockEarnings.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockEarnings.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockEarnings.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer Here: http://www.pennystockearnings.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)